NERV MINERVA NEUROSCIENCES INC US FDA Inspections 8-K Filing 2024 - FDA Response Letter Minerva Neurosciences, Inc. received a Complete Response Letter from the FDA regarding their New Drug Application for roluperidone for the treatment of negative symptoms in schizophrenia patients.Get access to all SEC 8-K filings of the MINERVA NEUROSCIENCES INC